(Q37399091)

20 August 2017

Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study (English)

1 reference

20 August 2017

1 reference

12

Hagop Kantarjian

1 reference

20 August 2017

13

Jorge E Cortes

1 reference

20 August 2017

5

Ian W Flinn

1 reference

20 August 2017

2

Moshe Talpaz

1 reference

20 August 2017

6

Dale Bixby

1 reference

20 August 2017

9

Tim Clackson

1 reference

20 August 2017

11

Frank G Haluska

1 reference

20 August 2017

7

Stephanie Lustgarten

1 reference

20 August 2017

Neil P Shah

1

1 reference

20 August 2017

Michael W N Deininger

3

1 reference

20 August 2017

Michael J Mauro

4

1 reference

20 August 2017

Joseph M Gozgit

8

1 reference

20 August 2017

Christopher D Turner

10

1 reference

20 August 2017

language of work or name

English

0 references

publication date

21 May 2013

1 reference

British Journal of Haematology

20 August 2017

1 reference

20 August 2017

162

1 reference

20 August 2017

4

1 reference

20 August 2017

548-552

1 reference

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866040

Ponatinib in refractory Philadelphia chromosome-positive leukemias

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866040

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866040

The clinical development of FLT3 inhibitors in acute myeloid leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866040

Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866040

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866040

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866040

FLT3: ITDoes matter in leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3866040

6 September 2017

Identifiers

DOI

10.1111/BJH.12382

1 reference

release_aime276cyzcbhcvohp4j7jh3yi

20 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/aime276cyzcbhcvohp4j7jh3yi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

20 August 2017

PubMed publication ID

23691988

1 reference